Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Antibe Therapeutics (ATBPF)
OTHER OTC:ATBPF
Antibe Therapeutics (ATBPF) Stock Price & Analysis
108 Followers
ATBPF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.11 - $0.89
Previous Close$0.22
Volume17.93K
Average Volume (3M)31.21K
Market Cap
$11.05M
Enterprise Value-$7.00M
Total Cash (Recent Filing)C$24.91M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)-0.8
Beta0.66
Next Earnings
Jun 27, 2024EPS Estimate
-$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding52,637,091
10 Day Avg. Volume32,253
30 Day Avg. Volume31,213
Standard Deviation0.19
R-Squared0.00113
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-37.42
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1.50Price Target Upside595.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Antibe Therapeutics News
PremiumCompany Announcements
Antibe Therapeutics Gains Creditor Protection
PremiumCompany Announcements
Antibe Therapeutics Seeks Creditor Protection
PremiumCompany Announcements
Antibe Therapeutics Faces FDA Hold and Legal Challenges
PremiumCompany Announcements
Antibe Therapeutics Showcases Non-Opioid Pain Drug
PremiumCompany Announcements
Antibe Showcases Pain Management Breakthrough
PremiumCompany Announcements
Antibe Therapeutics Faces Arbitration SetbackBulls Say, Bears Say
Bulls Say
Clinical TrialsPainReform Ltd. is currently enrolling patients for a Phase 3 Bunionectomy Study with results expected in the near future.
Drug DevelopmentCapricor Therapeutics, Inc. continues to make progress in their CAP-1002 and Exosome programs.
Financial HealthThe company's solid cash position is believed to be sufficient to fund the upcoming Phase II trial for otenaproxesul.
Bears Say
Competitive PositionCompetitor Vertex’s drug VX-548 demonstrated less pain relief than opioids, underscoring the difficulty of developing treatments that outperform current standards in the acute pain market.
Financial ObligationsAntibe has to refund Nuance’s $20M USD upfront payment plus $4M USD in interest, challenging the company’s financial stability.
Legal And Regulatory IssuesAntibe Therapeutics Inc. faces an unfavorable arbitration ruling which is likely to delay clinical operations with an unclear path forward.
---
Options Prices
Currently, No data available
---
Ownership Overview
28.56% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
71.44% Public Companies and
Individual Investors
ATBPF FAQ
What was Antibe Therapeutics’s price range in the past 12 months?
Antibe Therapeutics lowest stock price was $0.11 and its highest was $0.89 in the past 12 months.
What is Antibe Therapeutics’s market cap?
Currently, no data Available
When is Antibe Therapeutics’s upcoming earnings report date?
Antibe Therapeutics’s upcoming earnings report date is Jun 27, 2024 which is in 70 days.
How were Antibe Therapeutics’s earnings last quarter?
Antibe Therapeutics released its earnings results on Feb 14, 2024. The company reported -$0.058 earnings per share for the quarter, beating the consensus estimate of -$0.082 by $0.024.
Is Antibe Therapeutics overvalued?
According to Wall Street analysts Antibe Therapeutics’s price is currently Undervalued.
Does Antibe Therapeutics pay dividends?
Antibe Therapeutics does not currently pay dividends.
What is Antibe Therapeutics’s EPS estimate?
Antibe Therapeutics’s EPS estimate is -$0.07.
How many shares outstanding does Antibe Therapeutics have?
Antibe Therapeutics has 52,651,260 shares outstanding.
What happened to Antibe Therapeutics’s price movement after its last earnings report?
Antibe Therapeutics reported an EPS of -$0.058 in its last earnings report, beating expectations of -$0.082. Following the earnings report the stock price went up 1.493%.
Which hedge fund is a major shareholder of Antibe Therapeutics?
Currently, no hedge funds are holding shares in ATBPF
---
Antibe Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.50 (595.73% Upside)
$1.50 (595.73% Upside)
Insider Transactions
Bought Shares
Worth $22.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.78%
12-Months-Change
Fundamentals
Return on Equity
-52.43%
Trailing 12-Months
Asset Growth
-21.45%
Trailing 12-Months
Company Description
Antibe Therapeutics
Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. It operates through the Antibe Therapeutics, and Citagenix segments. The Antibe Therapeutics segment focuses on the development of pharmaceutical products. The Citagenix segment involves in the development and sale of regenerative medicines serving the dental and orthopedic market places. The company was founded by Andre Buret, John Wallace and Giuseppe Cirino on May 5, 2009 and is headquartered in Toronto, Canada.
---
ATBPF Stock 12 Months Forecast
Average Price Target
$1.50
▲(595.73% Upside)
Technical Analysis
Best Analysts Covering ATBPF
1 Year
1 Year Success Rate
2/15 ratings generated profit
1 Year Average Return
-38.15%
reiterated a buy rating 2 months ago
Copying Stefan Quenneville's trades and holding each position for 1 Year would result in 13.33% of your transactions generating a profit, with an average return of -38.15% per trade.
---